Hereditary Angioedema Therapeutics Market By Type of Therapy (C1 Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors), By Route of Administration (Injectable, Oral), By Indication (Acute Attacks, Prophylaxis), By End-User (Hospitals, Specialty Clinics, Home Care), and By Distribution Channel (Direct Sales, Third-Party Distributors); Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Hereditary Angioedema Therapeutics Market was valued at USD 2.8 Billion in 2024-e and will surpass USD 6.1 Billion by 2030; growing at a CAGR of 12.0% during 2025-2030.

The hereditary angioedema (HAE) therapeutics market has witnessed significant growth due to increasing awareness of rare diseases, technological advancements in treatment methods, and a growing patient pool. Hereditary angioedema is a genetic disorder marked by recurrent episodes of severe swelling, and the demand for effective therapies to manage symptoms and reduce the frequency of attacks is growing. The market comprises a variety of therapies, including C1 inhibitor replacement therapies, bradykinin B2 receptor antagonists, and kallikrein inhibitors. Additionally, there has been a surge in interest in prophylactic treatments that help manage the disease over time, leading to the development of new therapies.

With advancements in drug development, healthcare providers are focusing on offering personalized treatment options that suit the unique needs of each patient. This is driving innovation in the HAE therapeutics market, along with the rising adoption of injectable and oral therapies. Below, we will explore the key segments within the market, highlighting the largest or fastest-growing subsegments in each category.

C1 Inhibitor Replacement Therapy Is Largest Owing to Efficacy in Acute Attack Management

C1 inhibitor replacement therapy remains the largest subsegment within the therapeutic options for hereditary angioedema, primarily due to its proven efficacy in managing acute attacks. This therapy involves replacing the missing or dysfunctional C1 inhibitor protein in patients, which helps to control the overproduction of bradykinin, a key mediator of angioedema. It is widely used in both the prophylactic treatment of HAE and for acute attack management, offering immediate relief during attacks. The availability of intravenous formulations of C1 inhibitors has solidified its position as the standard of care in many countries.

The widespread adoption of C1 inhibitor replacement therapy is driven by its ability to rapidly mitigate symptoms during acute attacks and prevent complications. Furthermore, continued clinical advancements and improved formulations of C1 inhibitors, such as extended-release versions, are increasing its appeal. As a result, this treatment remains the most frequently prescribed and widely used therapy for HAE patients, contributing to its dominant market share in the global therapeutics landscape.

Oral Therapies Are Fastest Growing Owing to Convenience and Patient Preference

Among the various routes of administration for HAE treatments, oral therapies are the fastest-growing subsegment. Oral treatments, such as bradykinin B2 receptor antagonists and kallikrein inhibitors, offer significant advantages over injectable therapies, primarily in terms of patient convenience and compliance. These treatments allow patients to manage their condition at home without the need for frequent hospital visits or injections, leading to a more comfortable and less intrusive treatment regimen. As patient preference for non-invasive treatment options increases, the demand for oral therapies has surged, contributing to the rapid growth of this subsegment.

Additionally, the development of novel oral therapies with improved efficacy profiles and fewer side effects has made them more appealing to both patients and healthcare providers. This has been reflected in the market with increased approval of oral treatments for both acute attacks and prophylaxis. Oral therapies are expected to continue gaining market share as the focus on patient-centered care grows, positioning them as a key area for innovation and development within the HAE therapeutics space.

Prophylaxis Is Largest Indication Owing to Long-Term Disease Management

Prophylaxis for hereditary angioedema is the largest indication within the market, as it focuses on the long-term management of the disease to prevent recurrent attacks. Prophylactic therapies are essential for patients who experience frequent or severe episodes of angioedema, helping to reduce the frequency and intensity of attacks. These treatments are administered regularly, either through injectables or oral medications, to maintain a consistent level of therapeutic effect. Prophylactic treatments play a crucial role in improving the quality of life for patients and minimizing the risk of severe episodes that could lead to complications.

The preference for prophylactic treatments is driven by the need for effective long-term management options. As awareness of the benefits of preventative care grows, healthcare providers are increasingly recommending prophylaxis to patients, further solidifying its dominance in the market. The availability of innovative and more accessible prophylactic therapies is expected to fuel the continued growth of this segment, positioning it as the largest and most important indication within the global hereditary angioedema therapeutics market.

Hospitals Are Largest End-User Segment Owing to Acute Care Demand

Hospitals are the largest end-user segment in the hereditary angioedema therapeutics market, primarily driven by the acute care demands of HAE patients. Hospitals provide immediate access to specialized care, which is crucial during acute angioedema attacks. C1 inhibitor replacement therapies and other injectable treatments are often administered in hospitals under the supervision of healthcare professionals to ensure patient safety and efficacy. Given the nature of HAE, which involves unpredictable attacks, hospitals play a central role in managing patients during these critical periods, offering the necessary infrastructure and support for therapeutic interventions.

The hospital segment’s dominance is also due to the increasing prevalence of HAE and the need for emergency care. As more patients are diagnosed with hereditary angioedema, the demand for acute care services is expected to rise, further cementing the hospital segment's leading position in the market. Additionally, hospitals are increasingly collaborating with pharmaceutical companies to provide access to new therapies, enhancing the overall care continuum for patients suffering from HAE.

North America Is Largest Region Owing to Advanced Healthcare Infrastructure

North America is the largest regional market for hereditary angioedema therapeutics, largely due to its advanced healthcare infrastructure, high levels of awareness, and the presence of major pharmaceutical companies. The United States, in particular, is home to a large number of HAE patients, who benefit from access to cutting-edge treatments and therapies. Additionally, the regulatory environment in North America is highly favorable for the approval and commercialization of new therapies, contributing to the rapid introduction of novel treatment options. The high prevalence of HAE in North America, combined with the robust healthcare system, has positioned the region as the leader in the global HAE therapeutics market.

The North American market continues to benefit from significant investments in healthcare research, which are driving the development of more effective therapies for HAE. The ongoing efforts to improve the availability and affordability of treatments, coupled with increasing patient awareness, are expected to sustain North America's dominant position in the market throughout the forecast period.

Leading Companies and Competitive Landscape

The competitive landscape of the hereditary angioedema therapeutics market is characterized by the presence of several leading players, including Shire Pharmaceuticals (now part of Takeda), CSL Behring, Pharming Group, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals. These companies are at the forefront of developing and commercializing therapies for hereditary angioedema, focusing on both acute and prophylactic treatment options. Through strategic partnerships, acquisitions, and continuous innovation, these companies are expanding their product portfolios to meet the evolving needs of HAE patients.

The market is highly competitive, with companies focusing on developing differentiated treatments that offer improved efficacy, reduced side effects, and better patient compliance. As the demand for HAE therapies continues to grow, competition will likely intensify, leading to further advancements in the treatment landscape. Additionally, regulatory approvals and market access in emerging regions will be key factors in determining the success of market players in the global hereditary angioedema therapeutics market.

Recent Developments:

• Shire Pharmaceuticals (now part of Takeda) launched a new C1 inhibitor therapy, which has shown improved efficacy in controlling acute attacks of HAE.
• BioCryst Pharmaceuticals received FDA approval for Orladeyo, an oral kallikrein inhibitor for the prophylactic treatment of HAE.
• CSL Behring announced the expansion of its C1 Inhibitor product portfolio, offering additional treatment options for HAE patients in North America.
• Pharming Group N.V. entered into a partnership with Sobi to distribute its FDA-approved Ruconest for the treatment of acute HAE attacks in Europe.
• KalVista Pharmaceuticals signed a licensing agreement with Verenium Pharmaceuticals for the development of a next-generation oral therapy for HAE prevention, focusing on reducing attack frequency.

List of Leading Companies:

• Shire Pharmaceuticals
• Sanofi S.A.
• CSL Behring
• Pharming Group N.V.
• KalVista Pharmaceuticals
• Baxter International Inc.
• UCB S.A.
• Valeant Pharmaceuticals International
• BioCryst Pharmaceuticals
• Portola Pharmaceuticals
• Grifols, S.A.
• HaploPharma
• Sobi (Swedish Orphan Biovitrum)
• LFB Group
• Emergent BioSolutions

Report Scope: